Frankfurt Stock Exchange

Reliq Health Technologies, Inc. Announces Expansion of Contract with Large US Health Plan, Expects to Add 50,000 New Patients to iUGO Care

Retrieved on: 
Wednesday, January 10, 2024

The health plan operates Accountable Care Organizations (ACOs) and Health Maintenance Organizations (HMOs) in five States with over 3,000 doctors and more than 1,000,000 patients.

Key Points: 
  • The health plan operates Accountable Care Organizations (ACOs) and Health Maintenance Organizations (HMOs) in five States with over 3,000 doctors and more than 1,000,000 patients.
  • The expansion is expected to add over 50,000 new patients to Reliq’s iUGO Care platform by the end of 2025 at an average revenue of $65 per patient per month.
  • The iUGO Care Remote Patient Monitoring, Chronic Care Management and Behavioral Health Integration solutions Reliq will be providing will enable effective preventative care that allows the ACOs to achieve their cost and quality of care objectives.
  • iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery.

Reliq Health Technologies, Inc. Provides Update on Status of Management Cease Trade Order

Retrieved on: 
Tuesday, January 9, 2024

HAMILTON, Ontario, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) ("Reliq" or the "Company"), a rapidly growing global healthcare technology company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, is providing this update on the status of a management cease trade order granted on October 31, 2023 (the "MCTO") by the British Columbia Securities Commission under National Policy 12-203 – Management Cease Trade Order ("NP 12-203").

Key Points: 
  • HAMILTON, Ontario, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) ("Reliq" or the "Company"), a rapidly growing global healthcare technology company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, is providing this update on the status of a management cease trade order granted on October 31, 2023 (the "MCTO") by the British Columbia Securities Commission under National Policy 12-203 – Management Cease Trade Order ("NP 12-203").
  • During the MCTO, the general investing public will continue to be able to trade in the Company's listed common shares.
  • However, the Company's chief executive officer and chief financial officer will not be able to trade in the Company's shares.
  • Reliq Health Technologies is a rapidly growing global healthcare technology company that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market.

Argentina Lithium Announces Commencement of Trading on OTCQX Market and New Symbol

Retrieved on: 
Wednesday, January 10, 2024

VANCOUVER, BC, Jan. 10, 2024 /PRNewswire/ - Argentina Lithium & Energy Corp. (TSXV: LIT) (FSE: OAY3) (OTCQX: LILIF), ("Argentina Lithium" or the "Company") is pleased to announce that its common shares are now trading on the OTCQX Best Market under the ticker symbol of LILIF.

Key Points: 
  • VANCOUVER, BC, Jan. 10, 2024 /PRNewswire/ - Argentina Lithium & Energy Corp. (TSXV: LIT) (FSE: OAY3) (OTCQX: LILIF), ("Argentina Lithium" or the "Company") is pleased to announce that its common shares are now trading on the OTCQX Best Market under the ticker symbol of LILIF.
  • The OTCQX Best Market is the highest market tier of OTC Markets on which 12,000 U.S. and global securities trade.
  • Trading on OTCQX will enhance the visibility and accessibility of the Company to U.S. investors.
  • Argentina Lithium's common shares will continue to trade on the TSX Venture Exchange under the symbol LIT, and on the Frankfurt Stock Exchange under the symbol OAY3.

EQS-News: Bastei Lübbe AG reports successful Christmas business and raises forecast for financial year 2023/2024

Retrieved on: 
Monday, January 8, 2024

EBIT forecast revenue-driven increased again to a range of €12.5 million to €13.5 million (previously: €10 million to €11 million)

Key Points: 
  • EBIT forecast revenue-driven increased again to a range of €12.5 million to €13.5 million (previously: €10 million to €11 million)
    Cologne, 8 January 2024.
  • Bastei Lübbe AG (ISIN DE000A1X3YY0 ), a general-interest publisher listed in the Prime Standard of the Frankfurt Stock Exchange, continued the successful business development of the previous quarters in the Christmas business and recorded further profitable growth.
  • As a result, the Company raises its revenue forecast despite macroeconomic and geopolitical challenges and again increases its EBIT forecast for the financial year 2023/2024.
  • The EBIT forecast has been raised again, driven by revenues, and is now expected to range between €12.5 million and €13.5 million (previous year: €7.2 million).

EQS-News: Northern Data Group announces closing of Damoon acquisition

Retrieved on: 
Monday, January 8, 2024

Frankfurt/Main – 8 January 2024 – Northern Data AG (‘Northern Data Group’; Ticker symbol German stock market: NB2 , ISIN: DE000A0SMU87 ) today announces the completion of the acquisition of Damoon Limited, formerly Damoon Designated Activity Company (‘Damoon’)’ from Tether Group.

Key Points: 
  • Frankfurt/Main – 8 January 2024 – Northern Data AG (‘Northern Data Group’; Ticker symbol German stock market: NB2 , ISIN: DE000A0SMU87 ) today announces the completion of the acquisition of Damoon Limited, formerly Damoon Designated Activity Company (‘Damoon’)’ from Tether Group.
  • The closing of the transaction now makes Tether Group, one of the world’s most successful and innovative blockchain technology companies, the cornerstone shareholder in Northern Data Group.
  • In total, including the recently announced purchases , Northern Data Group now owns more than 18,000 NVIDIA H100 Tensor Core GPUs.
  • Thereby, Northern Data acquired 69.92% of Damoon, as well as 69.92% of the c. EUR 400 million shareholder loan granted to Damoon by Tether Group.

EQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb

Retrieved on: 
Monday, January 8, 2024

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes.
  • Following a successful Phase I study Bristol Myers Squibb announced that a Phase II study for BMS-986419 is scheduled to commence in 2024.
  • In March 2023, Bristol Myers Squibb and Evotec extended and expanded this partnership for an additional 8 years.
  • Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “As the first asset from our neuroscience partnership with Bristol Myers Squibb is moving towards a Phase II study, our partnership is still growing in the drug discovery phase as well.

Northern Data Group announces closing of Damoon acquisition

Retrieved on: 
Monday, January 8, 2024

FRANKFURT, Germany, Jan. 8, 2024 /PRNewswire/ -- Northern Data AG ('Northern Data Group') (Ticker symbol German stock market: NB2) (ISIN: DE000A0SMU87) today announces the completion of the acquisition of Damoon Limited, formerly Damoon Designated Activity Company ('Damoon')' from Tether Group.

Key Points: 
  • FRANKFURT, Germany, Jan. 8, 2024 /PRNewswire/ -- Northern Data AG ('Northern Data Group') (Ticker symbol German stock market: NB2) (ISIN: DE000A0SMU87) today announces the completion of the acquisition of Damoon Limited, formerly Damoon Designated Activity Company ('Damoon')' from Tether Group.
  • The closing of the transaction now makes Tether Group, one of the world's most successful and innovative blockchain technology companies, the cornerstone shareholder in Northern Data Group.
  • Thereby, Northern Data acquired 69.92% of Damoon, as well as 69.92% of the c. EUR 400 million shareholder loan granted to Damoon by Tether Group.
  • With the registration of a further increase of its share capital against contribution in kind by EUR 6,556,949 to EUR 48,734,180 on 3 January 2024, Northern Data Group acquired the remaining 30.08% of Damoon and of the shareholder loan granted to Damoon in implementation of the exercise of the call option granted to Northern Data Group in the Investment Agreement, as already announced in September 2023, thereby fully completing the acquisition of Damoon and the shareholder loan granted to Damoon.

EQS-News: First exit in 2024: Mutares has successfully sold VALTI to the company’s management

Retrieved on: 
Friday, January 5, 2024

Munich, January 5, 2024 – Mutares SE & Co. KGaA (ISIN: DE000A2NB650) has successfully sold its portfolio company VALTI to the company’s management.

Key Points: 
  • Munich, January 5, 2024 – Mutares SE & Co. KGaA (ISIN: DE000A2NB650) has successfully sold its portfolio company VALTI to the company’s management.
  • VALTI is a European manufacturer of seamless high-precision steel tubes serving the bearing manufacturer industry as well as a large mechanical base.
  • Robin Laik, CEO and founder of Mutares, comments: "We are pleased to announce the sale of our portfolio company VALTI.
  • As the portfolio grows, so do consulting revenues, which together with portfolio dividends and exit proceeds accrue to the Mutares Holding.

NJ Ayuk Departs from Centurion Law Firm to Pursue Other Energy Sector Endeavors

Retrieved on: 
Friday, January 5, 2024

JOHANNESBURG, Jan. 5, 2024 /PRNewswire/ -- NJ Ayuk, an internationally recognized lawyer and thought leader, recently announced that he will be stepping down from his role as chief executive officer at the prestigious law firm Centurion. Known for its pan-African work to bring equity and opportunity to the continent's energy market, Centurion has thrived under Ayuk's leadership for more than a decade.

Key Points: 
  • Ayuk has actively practiced law while guiding Centurion forward to foster progress and results-oriented development between African governments and leading natural gas and oil companies on national and global stages.
  • During his tenure, Ayuk has also nurtured up-and-coming advocates by providing training and oversight to new hires, with Centurion having developed more African lawyers than any other law firm in Africa.
  • He has aspirations to pursue a number of other endeavors within the energy sector for both charitable and entrepreneurial causes including the continuation of his work with the African Energy Chamber.
  • Ayuk also continues to be a best-selling author of works dedicated to creating awareness and advocacy regarding energy policy and economics.

EQS-News: Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I

Retrieved on: 
Thursday, January 4, 2024

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Owkin, a French-American techbio company today announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation (“I&I”).

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Owkin, a French-American techbio company today announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation (“I&I”).
  • The collaboration brings together highly complementary platforms and expertise to accurately select targets, discover and develop new therapeutics.
  • Evotec will receive R&D funding from Owkin and is eligible to earn performance milestone payments and royalties on product sales.
  • Dr Matthias Evers, Chief Business Officer of Evotec, commented: “Owkin and Evotec both feel there is something special brewing by convergence between A.I.